Skip to main content

BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.

Publication ,  Journal Article
Marchion, DC; Cottrill, HM; Xiong, Y; Chen, N; Bicaku, E; Fulp, WJ; Bansal, N; Chon, HS; Stickles, XB; Kamath, SG; Hakam, A; Li, L; Su, D ...
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research
October 2011

Despite initial sensitivity to chemotherapy, ovarian cancers (OVCA) often develop drug resistance, which limits patient survival. Using specimens and/or genomic data from 289 patients and a panel of cancer cell lines, we explored genome-wide expression changes that underlie the evolution of OVCA chemoresistance and characterized the BCL2 antagonist of cell death (BAD) apoptosis pathway as a determinant of chemosensitivity and patient survival.Serial OVCA cell cisplatin treatments were performed in parallel with measurements of genome-wide expression changes. Pathway analysis was carried out on genes associated with increasing cisplatin resistance (EC(50)). BAD-pathway expression and BAD protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemosensitivity and/or clinical outcome and as therapeutic targets.Induced in vitro OVCA cisplatin resistance was associated with BAD-pathway expression (P < 0.001). In OVCA cell lines and primary specimens, BAD protein phosphorylation was associated with platinum resistance (n = 147, P < 0.0001) and also with overall patient survival (n = 134, P = 0.0007). Targeted modulation of BAD-phosphorylation levels influenced cisplatin sensitivity. A 47-gene BAD-pathway score was associated with in vitro phosphorylated BAD levels and with survival in 142 patients with advanced-stage (III/IV) serous OVCA. Integration of BAD-phosphorylation or BAD-pathway score with OVCA surgical cytoreductive status was significantly associated with overall survival by log-rank test (P = 0.004 and P < 0.0001, respectively).The BAD apoptosis pathway influences OVCA chemosensitivity and overall survival, likely via modulation of BAD phosphorylation. The pathway has clinical relevance as a biomarker of therapeutic response, patient survival, and as a promising therapeutic target.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clinical cancer research : an official journal of the American Association for Cancer Research

DOI

EISSN

1557-3265

ISSN

1078-0432

Publication Date

October 2011

Volume

17

Issue

19

Start / End Page

6356 / 6366

Related Subject Headings

  • bcl-Associated Death Protein
  • Tumor Cells, Cultured
  • Signal Transduction
  • Phosphorylation
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Female
  • Drug Resistance, Neoplasm
  • Cisplatin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marchion, D. C., Cottrill, H. M., Xiong, Y., Chen, N., Bicaku, E., Fulp, W. J., … Lancaster, J. M. (2011). BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 17(19), 6356–6366. https://doi.org/10.1158/1078-0432.ccr-11-0735
Marchion, Douglas C., Hope M. Cottrill, Yin Xiong, Ning Chen, Elona Bicaku, William J. Fulp, Nisha Bansal, et al. “BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 17, no. 19 (October 2011): 6356–66. https://doi.org/10.1158/1078-0432.ccr-11-0735.
Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Oct;17(19):6356–66.
Marchion, Douglas C., et al. “BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 17, no. 19, Oct. 2011, pp. 6356–66. Epmc, doi:10.1158/1078-0432.ccr-11-0735.
Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen D-T, Lancaster JM. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Oct;17(19):6356–6366.

Published In

Clinical cancer research : an official journal of the American Association for Cancer Research

DOI

EISSN

1557-3265

ISSN

1078-0432

Publication Date

October 2011

Volume

17

Issue

19

Start / End Page

6356 / 6366

Related Subject Headings

  • bcl-Associated Death Protein
  • Tumor Cells, Cultured
  • Signal Transduction
  • Phosphorylation
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Female
  • Drug Resistance, Neoplasm
  • Cisplatin